Streetbeat News

Analyst Ratings

SEDG

Analyst ratings for SolarEdge Technologies (NASDAQ:SEDG) show a mix of bullish and bearish perspectives with 19 analysts providing ratings. The average 12-month price target is $86.0, down 10.77% from the previous $96.38. Recent actions include both downgrades and maintenance of ratings, reflecting dynamic market conditions. SolarEdge faces challenges with a significant revenue decline of -64.52%, a net margin of -51.38%, and below-average ROE and ROA, indicating potential profitability and efficiency issues.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:01 pm

INTC

Deep-pocketed investors have shown a bullish sentiment towards Intel (NASDAQ:INTC), with a significant surge in options activity reported by Benzinga. The activity includes 15 extraordinary options trades, with 60% being bullish and 40% bearish, focusing on a price window from $25.0 to $70.0. Notable trades include bullish calls with expiration dates in 2024 and 2025, and bearish puts for 2024. Intel's current trading volume is 10,497,011, with a price increase of 0.86% to $44.38. Analysts have mixed views, with an average price target of $34.33, and ratings ranging from Sell to Neutral.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:01 pm

DKNG

Financial analysts have observed a bearish trend in DraftKings (NASDAQ:DKNG) options trading, with a significant number of trades indicating a bearish sentiment despite some bullish activity. The trading activity suggests a target price range of $40.0 to $45.0 for DraftKings in the coming months. DraftKings, a leader in online sports and casino gambling, is currently live with online sports betting in 24 states and iGaming in seven states. Despite the bearish options sentiment, market experts have issued positive ratings for DKNG, with a consensus target price of $55.2.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:00 pm

PFE

Pfizer (NYSE:PFE) has seen a significant amount of options trading activity, with a bullish sentiment from the majority of investors. Analysis of 17 trades shows a preference for calls over puts, indicating expectations of a price increase. The trading activity suggests a price target range between $18.0 and $44.0. Recent analyst ratings have varied, with an average target price of $42.0. Pfizer's current market status shows a slight price increase with potential overbought indicators. The company's financial health remains strong, with a diverse portfolio of prescription drugs and vaccines.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:00 pm

DUOL

Duolingo (NASDAQ:DUOL) has been analyzed by 8 analysts in the last three months, showing a diverse range of perspectives. The average 12-month price target for DUOL is $240.12, with a high estimate of $282.00 and a low of $160.00, marking an 18.09% increase from the previous average of $203.33. Analysts from firms including JP Morgan, Needham, B of A Securities, Goldman Sachs, Barclays, Piper Sandler, and UBS have updated their ratings and price targets, reflecting a positive outlook on Duolingo's financial performance, which boasts a revenue growth rate of 45.42%, a net margin of 8.03%, and a debt-to-equity ratio of 0.04.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:00 pm

MCB

Metropolitan Bank Holding (NYSE:MCB) has seen a shift in analyst sentiment over the last quarter, with all 4 analysts maintaining a somewhat bullish stance despite lowering their 12-month price targets, indicating a negative sentiment shift. The average price target now stands at $59.00, down 11.94% from previous estimates. The bank's financial performance shows a decline in revenue growth by -9.53% for the last 3 months as of December 31, 2023, but it maintains strong profitability indicators such as a net margin of 22.8%, ROE of 2.24%, and ROA of 0.21%. Its debt-to-equity ratio is below the industry average, suggesting a conservative financial approach.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:00 pm

LXU

LSB Industries (NYSE:LXU) received mixed analyst ratings with a shift towards a more bearish outlook in the last 30 days. The average 12-month price target is now $8.69, down 20.13% from the previous average, with analysts from RBC Capital, UBS, and Piper Sandler adjusting their ratings and price targets. LSB Industries, a manufacturer of chemical products, faces challenges with a significant revenue decline of -43.24% and a high debt-to-equity ratio of 1.18, despite a strong net margin of -4.03% and ROA of -0.41%.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 3:00 pm

MSFT

NVDA

Wedbush analyst Dan Ives highlighted the significant impact of Nvidia's H100 GPU on tech spending, suggesting every $1 spent on the GPU could lead to an additional $10-$12 in tech ecosystem spending. This reflects the broader AI revolution's influence on tech investments. Ives previously noted Nvidia's Q4 results as the beginning of an AI spending wave. Meanwhile, Microsoft's CEO emphasized the rapid AI adoption across sectors, and ARK's Cathie Wood expressed concerns over a potential semiconductor market correction.

Portfolio Pulse from Rounak Jain

March 11, 2024 | 3:00 pm

CDMO

Stephens & Co. analyst Jacob Johnson maintains an Overweight rating on Avid Bioservices (CDMO) but lowers the price target from $15 to $12.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 3:00 pm

NDLS

Truist Securities analyst Jake Bartlett has maintained a Buy rating on Noodles & Co. (NDLS) but lowered the price target from $5 to $4.

Portfolio Pulse from Benzinga Newsdesk

March 11, 2024 | 2:58 pm